The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer

Annals of Oncology : Official Journal of the European Society for Medical Oncology
H OksefjellClaes G Tropé

Abstract

The aim of this study was to investigate the benefit of secondary cytoreduction (SCR) in the first relapse in epithelial ovarian cancer and to attempt to define selection criteria for SCR. A retrospective population-based study on recorded information from 789 patients treated at the Norwegian Radium Hospital during 1985-2000 for their initial recurrence. In all, 217 had SCR and 572 were treated with chemotherapy alone. Median survival time (MST) was 1.1 years for the chemotherapy group. Complete optimal cytoreduction (COC) was achieved in 35% of all 217 patients, in 49% of the patients operated with debulking intent and in 52% if bowel surgery was done with debulking intent. MST was 4.5 versus 0.7 years for 0 versus>2 cm residual disease, respectively. Residual disease after SCR, treatment-free interval (TFI) and age were found to be prognostic factors for overall survival (OS) in multivariate analysis. Localised tumour was found to be the only significant factor to predict COC. SCR followed by chemotherapy gives a clear survival benefit compared with chemotherapy and should be offered when the tumour is localised. The combination of COC, TFI >24 months and age </=39 years identifies a group of patients with the best OS.

References

Feb 15, 1993·Cancer·J T ThigpenT Khansur
Aug 23, 2002·Southern Medical Journal·Ronald C Hamdy
Sep 5, 2002·Cancer·Robert E BristowFredrick J Montz
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J PfistererUNKNOWN EORTC GCG
Dec 14, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J PfistererUNKNOWN AGO Ovarian Cancer Study Group (AGO-OVAR)
Jan 4, 2006·American Journal of Obstetrics and Gynecology·Ali AyhanTurkan Kucukali
Sep 30, 2006·Annals of Surgical Oncology·Philipp HarterUNKNOWN AGO Ovarian Cancer Study Group
Nov 15, 2006·The Journal of Obstetrics and Gynaecology Research·Aya MatsumotoShingo Fujii
Jan 2, 2007·Annals of Surgical Oncology·Pierluigi Benedetti PaniciRoberto Angioli
Jun 26, 2007·Gynecologic Oncology·Stephen J TebesMitchel S Hoffman

❮ Previous
Next ❯

Citations

Oct 28, 2009·Journal of Oncology·Igor E Martinek, Sean Kehoe
Sep 2, 2011·Women's Health·Florian HeitzPhilipp Harter
Apr 19, 2015·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Ayshea Hameeduddin, Anju Sahdev
Oct 21, 2016·The British Journal of Radiology·Katrijn L M MichielsenVincent Vandecaveye
Mar 2, 2013·The Cochrane Database of Systematic Reviews·Thuria Al RawahiKhadra Galaal
Jan 25, 2014·Journal of Gynecologic Oncology·Hiroaki KajiyamaFumitaka Kikkawa
Sep 17, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·René H M VerheijenUNKNOWN Council of the European Society of Gynaecologic Oncology
Jan 25, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Enora LaasElisabeth Chéreau
Mar 7, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Hiroaki KajiyamaFumitaka Kikkawa
Apr 14, 2010·Nature Reviews. Clinical Oncology·Stavroula KyriaziNandita M deSouza
May 26, 2010·Current Opinion in Oncology·Rowan E Miller, Gordon J S Rustin
Jul 9, 2010·Journal of Gynecologic Oncology·Karin K Shih, Dennis S Chi
Aug 20, 2010·Journal of Surgical Oncology·Ioannis BiliatisAris Antsaklis
Jan 9, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Philipp HarterAndreas du Bois
Oct 18, 2015·International Journal of Clinical Oncology·Takeo MinaguchiHiroyuki Yoshikawa
Nov 3, 2011·Current Oncology Reports·Marcia Hall, Gordon Rustin
Aug 11, 2010·Annals of Surgical Oncology·Christina FotopoulouJalid Sehouli
Aug 25, 2012·Current Oncology Reports·Philipp HarterAndreas du Bois
Jul 11, 2009·Expert Review of Anticancer Therapy·Philipp HarterAndreas du Bois
Aug 30, 2014·Journal of Visceral Surgery·N BakrinO Glehen
Jun 18, 2019·American Journal of Obstetrics and Gynecology·Allison GockleyAlexi A Wright

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.